Booth 1743
Lausanne, Vaud, Switzerland
Vandria SA is a biopharmaceutical spin-off from Amazentis SA and was incorporated in Switzerland in 2021. The company discovers and develops novel small molecules that can effectively induce mitophagy to treat age-related and chronic diseases. Vandria is in the the IND-enabling stage with two lead candidates that have shown highly promising results in vitro and in vivo. The first clinical trials are expected to begin in Q2-2024

Through a unique drug discovery engine and a dedicated R&D team, we have developed and patented a range of novel small molecules that specifically can target the brain, muscle tissue, and other tissues.

Vandria is seeking investors to complete its investor syndicate for a Series A financing round which will be concluded in Q3-2023.
The disease focus is:

CNS: Mild Cognitive Impairment, ALS
Muscle: Sporadic Inclusion Body Myositis, Sarcopenia
Other: Inflammatory diseases, immuno-oncology

Vandria is open to discuss partnering opportunities with biotech and pharmaceutical companies, both in relation to our mitophagy inducer pipeline and our novel ferroptosis inhibitors.
Focus Areas